HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET.

Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discovery, including prolonged screening timelines and historically undruggable targets.

MindWalk’s Perspective

MindWalk is a biology company that built AI on top of 25 years of wet-lab expertise. Its HYFT technology powers ReefIQ, the biological context layer for life sciences, enriching biological data at ingestion and connecting it across a continuously evolving knowledge representation of 660 million biological patterns and 25 billion relationships, with the LensAI platform serving as the reasoning and application layer on top. Because predictions are grounded in evolutionary constraint rather than statistical correlation, the architecture is designed to keep both AI models and autonomous agents from hallucinating in the highest-consequence drug discovery workflows. On the panel, Dr. Bath is expected to discuss why the durable asset in biological AI is the enriched context layer rather than any individual model, and how that layer makes agentic AI trustworthy enough to deploy in regulated workflows. LensAI is already in contracted, recurring arrangements with life-sciences customers today.

“The hardest problem in drug discovery was never a shortage of compute or models - it’s that biological data arrives fragmented, and a model reasoning over fragments will confidently get it wrong. Our work grounds that reasoning in what evolution has already constrained, so the biology is connected and real before a model ever acts on it. Paired with compute built for this kind of memory-heavy work, that’s what makes agentic AI trustworthy enough for the highest-consequence workflows. Biology, context, and compute - that convergence is what I’m looking forward to discussing,” said Dr. Jennifer Bath, PhD, Chief Executive Officer and President of MindWalk Holdings Corp.

Schreibe Deinen Kommentar